Kaposi's Sarcoma in HIV‐infected patients in South Africa: Multicohort study in the antiretroviral therapy era
Open Access
- 12 April 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (11) , 2644-2652
Abstract
The incidence of Kaposi's Sarcoma (KS) is high in South Africa but the impact of antiretroviral therapy (ART) is not well defined. We examined incidence and survival of KS in HIV‐infected patients enrolled in South African ART programs. We analyzed data of three ART programs: Khayelitsha township and Tygerberg Hospital programs in Cape Town and Themba Lethu program in Johannesburg. We included patients aged >16 years. ART was defined as a regimen of at least three drugs. We estimated incidence rates of KS for patients on ART and not on ART. We calculated Cox models adjusted for age, sex and time‐updated CD4 cell counts and HIV‐1 RNA. A total of 18,254 patients (median age 34.5 years, 64% female, median CD4 cell count at enrolment 105 cells/μL) were included. During 37,488 person‐years follow‐up 162 patients developed KS. The incidence was 1,682/100,000 person‐years (95% confidence interval [CI] 1,406–2,011) among patients not receiving ART and 138/100,000 person‐years (95% CI 102–187) among patients on ART. The adjusted hazard ratio comparing time on ART with time not on ART was 0.19 (95% CI 0.13–0.28). Low CD4 cell counts (time‐updated) and male sex were also associated with KS. Estimated survival of KS patients at one year was 72.2% (95% CI 64.9–80.2) and higher in men than in women. The incidence of KS is substantially lower on ART than not on ART. Timely initiation of ART is essential to prevent KS and KS‐associated morbidity and mortality in South Africa and other regions in Africa with a high burden of HIV.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (U01AI069924)
- National Cancer Institute (3U01AI069924-05S2)
- Swiss National Science Foundation (PZ00P3_136620_3)
- National Institute of Allergy and Infectious Diseases (K01AI083097)
- President's Emergency Plan for AIDS Relief
This publication has 43 references indexed in Scilit:
- Risk of Kaposi sarcoma during the first months on combination antiretroviral therapyAIDS, 2013
- Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settingsCurrent Opinion in Oncology, 2012
- A Randomized Controlled Trial of Highly Active Antiretroviral Therapy Versus Highly Active Antiretroviral Therapy and Chemotherapy in Therapy-Naive Patients With HIV-Associated Kaposi Sarcoma in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi SarcomaCancer Letters, 2011
- The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registryAIDS, 2011
- Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV SeroconversionJNCI: Journal of the National Cancer Institute, 2010
- Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South AfricaTropical Medicine & International Health, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009
- Combined Antiretroviral Treatment Initiation During Hospitalization: Outcomes in South African AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapyBritish Journal of Cancer, 2008